For your convenience, we have created interactive editions of several investor documents and packed them into this eKit. These interactive documents are designed for comfortable reading and easy navigation.

RSS Feeds

Date Title   05/16/13 Amgen To Present At The UBS Global Life Sciences Conference 05/15/13 New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer 05/15/13 Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting 05/09/13 Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China 05/07/13 Amgen Announces Top-Line Results of Vectibix® (panitumumab) Phase 3 Head-to-Head Study Against Erbitux® (cetuximab) in Metastatic Colorectal Cancer 05/01/13 Four Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California 04/23/13 Amgen's First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96 04/18/13 Amgen Announces Webcast of 2013 First Quarter Financial Results 03/19/13 Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma 03/06/13 Amgen Announces 2013 Second Quarter Dividend